• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    2/4/25 4:30:48 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRPX alert in real time by email
    false 0001708331 0001708331 2025-02-03 2025-02-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): February 3, 2025

     

    Virpax Pharmaceuticals, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40064   82-1510982
    (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

     

    1055 Westlakes Drive, Suite 300

    Berwyn, PA 19312

    (Address of principal executive offices, including zip code)

     

    (610) 727-4597

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class:   Trading Symbol   Name of Each Exchange on which Registered
    Common Stock, par value $0.00001 per share   VRPX   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On February 3, 2025, Mr. Jaydriane (Jay) Panis, a member of the Board of Directors (the “Board”) of Virpax Pharmaceuticals, Inc. (the “Company”), notified the Board of his resignation from the Board and the Board’s Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, effective immediately.

     

    Mr. Panis stated that his resignation was due to compliance requirements related to his current employer. His resignation was not due to any disagreement with the Company on any matter relating to its operations, policies, or practices.

     

    The Company and the Board express their appreciation for Mr. Panis’s service and contributions and will begin the process of identifying a qualified independent director to fill the resulting vacancy in accordance with applicable regulatory and governance requirements.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

    Signature

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      VIRPAX PHARMACEUTICALS, INC.
         
    Dated: February 4, 2025 By: /s/ Jatinder Dhaliwal
        Jatinder Dhaliwal
        Chief Executive Officer

     

     

     

    Get the next $VRPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRPX

    DatePrice TargetRatingAnalyst
    More analyst ratings